4D Molecular Therapeutics(FDMT) - 2025 Q2 - Quarterly Results

Exhibit 99.1 4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones EMERYVILLE, Calif., August 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today reported Q2 2025 financial results, provided operational highlights and out ...